Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®

NCT01043029 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01043029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01043029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2010
Completion date
July 31, 2012
Enrollment
302 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2